GAM
CORT icon

Gotham Asset Management’s Corcept Therapeutics CORT Stock Holding History

Gotham Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$722K Buy
17,918
+566
+3% +$21.2K ﹤0.01% 1400
2025
Q4 		$604K Sell
17,352
-10
-0.1% -$785 ﹤0.01% 1389
2025
Q3 		$1.44M Buy
17,362
+50
+0.3% +$3.62K 0.01% 1090
2025
Q2 		$1.27M Sell
17,312
-111
-0.6% -$8.05K 0.01% 1068
2025
Q1 		$1.99M Sell
17,423
-1,714
-9% -$104K 0.02% 804
2024
Q4 		$964K Buy
19,137
+523
+3% +$27.4K 0.01% 928
2024
Q3 		$861K Sell
18,614
-6,341
-25% -$225K 0.01% 946
2024
Q2 		$811K Sell
24,955
-13,717
-35% -$376K 0.01% 948
2024
Q1 		$974K Buy
38,672
+21,009
+119% +$496K 0.01% 858
2023
Q4 		$574K Sell
17,663
-73
-0.4% -$2K 0.01% 947
2023
Q3 		$483K Sell
17,736
-4,066
-19% -$118K 0.01% 972
2023
Q2 		$485K Sell
21,802
-7,405
-25% -$170K 0.01% 981
2023
Q1 		$633K Sell
29,207
-14,458
-33% -$317K 0.02% 879
2022
Q4 		$887K Buy
43,665
+5,510
+14% +$138K 0.03% 727
2022
Q3 		$978K Sell
38,155
-9,166
-19% -$245K 0.03% 658
2022
Q2 		$1.13M Sell
47,321
-2,119
-4% -$46.2K 0.04% 538
2022
Q1 		$1.11M Buy
49,440
+594
+1% +$12.6K 0.03% 533
2021
Q4 		$967K Buy
48,846
+30,279
+163% +$614K 0.03% 547
2021
Q3 		$365K Buy
18,567
+3,188
+21% +$66.7K 0.01% 751
2021
Q2 		$338K Sell
15,379
-1,373
-8% -$30.6K 0.01% 800
2021
Q1 		$399K Sell
16,752
-9,811
-37% -$262K 0.02% 742
2020
Q4 		$695K Sell
26,563
-16,822
-39% -$354K 0.02% 639
2020
Q3 		$755K Buy
43,385
+14,374
+50% +$229K 0.02% 629
2020
Q2 		$488K Sell
29,011
-43,332
-60% -$609K 0.01% 746
2020
Q1 		$860K Sell
72,343
-5,791
-7% -$71.7K 0.02% 584
2019
Q4 		$945K Buy
78,134
+29,674
+61% +$413K 0.02% 638
2019
Q3 		$685K Sell
48,460
-27,727
-36% -$341K 0.01% 673
2019
Q2 		$849K Sell
76,187
-39,642
-34% -$442K 0.01% 670
2019
Q1 		$1.36M Sell
115,829
-6,964
-6% -$86.5K 0.02% 574
2018
Q4 		$1.64M Buy
122,793
+66,533
+118% +$879K 0.03% 542
2018
Q3 		$789K Sell
56,260
-13,761
-20% -$192K 0.01% 655
2018
Q2 		$1.1M Buy
70,021
+49,309
+238% +$858K 0.02% 578
2018
Q1 		$341K Buy
20,712
+2,878
+16% +$53.3K ﹤0.01% 786
2017
Q4 		$322K Sell
17,834
-48,616
-73% -$881K ﹤0.01% 798
2017
Q3 		$1.28M Buy
66,450
+6,793
+11% +$101K 0.02% 577
2017
Q2 		$704K Buy
59,657
+47,968
+410% +$521K 0.01% 689
2017
Q1 		$128K Sell
11,689
-26,321
-69% -$231K ﹤0.01% 947
2016
Q4 		$276K Buy
38,010
+17,102
+82% +$134K ﹤0.01% 830
2016
Q3 		$136K Buy
20,908
+5,884
+39% +$34.2K ﹤0.01% 887
2016
Q2 		$82K Buy
+15,024
New +$78.2K ﹤0.01% 926
2016
Q1 		– Sell
-17,347
Closed -$86K – 987
2015
Q4 		$86K Buy
17,347
+126
+0.7% +$568 ﹤0.01% 845
2015
Q3 		$65K Buy
+17,221
New +$87.4K ﹤0.01% 891

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Gotham Asset Management's CORT Position: Q1 2026 in Review

Gotham Asset Management increased its Corcept Therapeutics (CORT) stake by 3.3% in Q1 2026, buying an estimated $21.2K and bringing the position to 17,918 shares worth $722K. The position accounts for ﹤0.01% of the portfolio, ranked #1400.

Gotham Asset Management first reported a position in CORT in Q3 2015 and has held it in 42 quarters since. The position peaked at $1.99M in Q1 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Gotham Asset Management held 17,918 shares of Corcept Therapeutics worth $722K as of Q1 2026.
  • Gotham Asset Management bought 566 Corcept Therapeutics shares in Q1 2026, an estimated $21.2K.
  • Corcept Therapeutics made up ﹤0.01% of Gotham Asset Management's portfolio in Q1 2026, its #1400 holding.
  • Gotham Asset Management first reported a position in Corcept Therapeutics in Q3 2015 and has held it in 42 quarters since.
  • Gotham Asset Management's Corcept Therapeutics position peaked at $1.99M in Q1 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Gotham Asset Management's 13F filing for Q1 2026, filed 15 May 2026.